Briakinumab
| Briakinumab (suggested INN ) | ||
|---|---|---|
| Mass / length primary structure | approx. 144 kDa | |
| Identifier | ||
| External IDs |
|
|
| Drug information | ||
| Drug class | Monoclonal antibodies | |
Briakinumab (ABT-874) is a monoclonal antibody , which as a drug for the treatment of psoriasis (psoriasis) from the pharmaceutical company Abbott Laboratories has been developed. In January 2011 the application for approval that had already been submitted was withdrawn.
Mechanism of action
Psoriasis is a chronic inflammatory autoimmune disease of the skin, characterized by an excessive growth of keratinocytes (skin-forming cells) in the epidermis . The triggers can include environmental influences such as sunburn or bacterial antigens , which stimulate the keratinocytes to increase the production of inflammation mediators . These trigger a number of secondary reactions in the dermis located under the epidermis , including a. the expression of adhesion molecules on endothelial cells of small blood vessels, leading to the invasion of neutrophilic granulocytes and T-lymphocytes leads and inflammatory subsequently to further distribution cytokines .
The cytokines secreted by macrophages and dendritic cells include IL-12 and IL-23. Both cytokines are heterodimeric proteins that share the so-called p40 subunit. With the p40 subunit, both bind to the IL-12ß1 receptor of T lymphocytes, which thereby release other inflammatory substances and promote the inflammatory process in psoriasis. Briakinumab is said to intervene in this process by binding to the p40 subunit of IL-12 and IL-23 and thereby inhibiting the subsequent inflammatory processes.
See also
Individual evidence
- ↑ European Medicines Agency: Ozespa withdrawal (PDF; 81 kB), January 20, 2011, EMA / 40202/2011.
- ↑ T. Vergou, XT (2009). Targeting the IL-12 / IL-23 cytokine family in the treatment of psoriatic disease. Expert Rev. Dermatol. , 3 (4): 453-463.
- ^ X T. Lima, KA (2009). Briakinumab. Expert Opin. Biol. Ther., Early online.